全文获取类型
收费全文 | 20879篇 |
免费 | 1450篇 |
国内免费 | 409篇 |
专业分类
耳鼻咽喉 | 107篇 |
儿科学 | 388篇 |
妇产科学 | 292篇 |
基础医学 | 2740篇 |
口腔科学 | 278篇 |
临床医学 | 2753篇 |
内科学 | 4490篇 |
皮肤病学 | 359篇 |
神经病学 | 975篇 |
特种医学 | 440篇 |
外国民族医学 | 1篇 |
外科学 | 1777篇 |
综合类 | 1423篇 |
现状与发展 | 2篇 |
一般理论 | 47篇 |
预防医学 | 3287篇 |
眼科学 | 302篇 |
药学 | 1367篇 |
21篇 | |
中国医学 | 535篇 |
肿瘤学 | 1154篇 |
出版年
2024年 | 58篇 |
2023年 | 2105篇 |
2022年 | 3199篇 |
2021年 | 6800篇 |
2020年 | 4470篇 |
2019年 | 257篇 |
2018年 | 240篇 |
2017年 | 193篇 |
2016年 | 223篇 |
2015年 | 241篇 |
2014年 | 392篇 |
2013年 | 411篇 |
2012年 | 312篇 |
2011年 | 390篇 |
2010年 | 342篇 |
2009年 | 323篇 |
2008年 | 305篇 |
2007年 | 319篇 |
2006年 | 307篇 |
2005年 | 241篇 |
2004年 | 253篇 |
2003年 | 221篇 |
2002年 | 145篇 |
2001年 | 129篇 |
2000年 | 107篇 |
1999年 | 87篇 |
1998年 | 82篇 |
1997年 | 60篇 |
1996年 | 74篇 |
1995年 | 43篇 |
1994年 | 29篇 |
1993年 | 39篇 |
1992年 | 27篇 |
1991年 | 29篇 |
1990年 | 22篇 |
1989年 | 13篇 |
1988年 | 11篇 |
1987年 | 8篇 |
1985年 | 36篇 |
1984年 | 37篇 |
1983年 | 23篇 |
1982年 | 23篇 |
1981年 | 23篇 |
1980年 | 16篇 |
1979年 | 13篇 |
1977年 | 10篇 |
1976年 | 5篇 |
1975年 | 10篇 |
1974年 | 6篇 |
1973年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
81.
Mehdi Karimi Shahri Hamid R. Niazkar Fariba Rad 《International journal of laboratory hematology》2021,43(2):160-168
In December 2019, a new type of coronavirus was detected for the first time in Wuhan, Hubei Province, China. According to the reported data, the emerging coronavirus has spread worldwide, infecting more than fifty-seven million individuals, leading to more than one million deaths. The current study aimed to review and discuss the hematological findings of COVID-19. Laboratory changes and hematologic abnormalities have been reported repeatedly in COVID-19 patients. WBC count and peripheral blood lymphocytes are normal or slightly reduced while these indicators may change with the progression of the disease. In addition, several studies demonstrated that decreased hemoglobin levels in COVID-19 patients were associated with the severity of the disease. Moreover, thrombocytopenia, which is reported in 5%-40% of patients, is known to be associated with poor prognosis of the disease. COVID-19 can present with various hematologic manifestations. In this regard, accurate evaluation of laboratory indicators at the beginning and during COVID-19 can help physicians to adjust appropriate treatment and provide special and prompt care for those in need. 相似文献
82.
《Primary Care Diabetes》2021,15(6):910-917
Background and aimsClinical and laboratory predictors of adverse clinical course and death in COVID-19 patients urgently need to be identified. So far, the association between HbA1c and in-hospital mortality of COVID-19 remains a controversial issue. The aim of this study is to analyze predictive value of HbA1c for adverse prognosis in COVID-19.MethodsBoth Chinese and English databases were systematically searched using specific keywords associated with the aims until November 21th, 2020. The Newcastle-Ottawa Scale (NOS) was used for quality assessment. A Statistical analysis was carried out using Review Manager 5.3 and STATA 15.1.ResultsNine clinical trials were included in this study involving 2577 subjects. The results indicate that the association between elevated HbA1c referred as a continuous variable and adverse prognosis of COVID-19 was not significant (OR, 1.02; 95%CI, 0.95–1.09). However, higher HbA1c levels regarded as a dichotomous variable contributed to an increase mortality of COVID-19 (OR, 2.300; 95%CI, 1.679–3.150). Results were stable in a sensitivity analysis. More studies are needed to demonstrate the effect of HbA1c on hospital mortality.ConclusionProlonged uncontrolled hyperglycemia increases the risk of adverse prognosis in COVID-19. Patients with higher HbA1c should be monitored strictly to minimize the risk of adverse prognosis in COVID-19. 相似文献
83.
84.
85.
《Transfusion and apheresis science》2020,59(4):102855
The activation of the innate and adaptive immune systems by SARS-CoV-2 causes the release of several inflammatory cytokines, including IL-6. The inflammatory hypercytokinemia causes immunopathological changes in the lungs including vascular leakage, and alveolar edema. As a result of these changes in the lungs, hypoxia and acute respiratory distress syndrome occur in patients with COVID-19. Even though there are clinical trials on the development of therapeutics and vaccines, there are currently no licensed vaccines or therapeutics for COVID-19. Pharmacological approaches have shown poor results in sepsis-like syndromes caused by the hypercytokinemia. Suppressing the cytokine storm is an important way to prevent the organ damage in patients with COVID-19. Extracorporeal blood purification could be proposed as an adjunctive therapy for sepsis, aiming to control the associated dysregulation of the immune system, which is known to protect organ functions. Several extracorporeal blood purification therapies are now available, and most of them target endotoxins and/or the cytokines and aim improving the immune response. For this purpose, plasmapheresis and immunoadsorption may be an important adjunctive treatment option to manage the complications caused by cytokine storm in critically ill patients with COVID-19. 相似文献
86.
87.
《Clinical oncology (Royal College of Radiologists (Great Britain))》2020,32(6):347-353
The current COVID-19 pandemic presents a substantial obstacle to cancer patient care. Data from China as well as risk models suppose that cancer patients, particularly those on active, immunosuppressive therapies are at higher risks of severe infection from the illness. In addition, staff illness and restructuring of services to deal with the crisis will inevitably place treatment capacities under significant strain. These guidelines aim to expand on those provided by NHS England regarding cancer care during the coronavirus pandemic by examining the known literature and provide guidance in managing patients with urothelial and rarer urinary tract cancers. In particular, they address the estimated risk and benefits of standard treatments and consider the alternatives in the current situation. As a result, it is recommended that this guidance will help form a framework for shared decision making with patients. Moreover, they do not advise a one-size-fits-all approach but recommend continual assessment of the situation with discussion within and between centres. 相似文献
88.
J. Alarcón-Rodríguez M. Fernández-Velilla A. Ureña-Vacas J.J. Martín-Pinacho J.A. Rigual-Bobillo A. Jaureguízar-Oriol L. Gorospe-Sarasúa 《Radiologia》2021,63(3):258-269
Most of the patients who overcome the SARS-CoV-2 infection do not present complications and do not require a specific follow-up, but a significant proportion (especially those with moderate / severe clinical forms of the disease) require clinicalradiological follow-up. Although there are hardly any references or clinical guidelines regarding the long-term follow-up of post-COVID-19 patients, radiological exams are being performed and monographic surveillance consultations are being set up in most of the hospitals to meet their needs. The purpose of this work is to share our experience in the management of the post-COVID-19 patient in two institutions thathave had a high incidence of COVID-19 and to propose general follow-uprecommendations from a clinical and radiological perspective. 相似文献
89.
90.
《Clinical Lymphoma, Myeloma & Leukemia》2020,20(11):720-723
Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia. 相似文献